Silverarc Capital Management, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Silverarc Capital Management, LLC reported 72 stock positions worth $356.6 million. Its top holding was Merus (MRUS) at 7.2% of the portfolio, followed by Solid Biosciences (SLDB, 4.9%) and Morphic (MORF, 4.8%). Compared with Q4 2023, it opened 30 new positions, sold out of 21, added to 9 and reduced 31. The biggest buy was Solid Biosciences (SLDB, shares +123%) and the biggest sale an exit from Medtronic (MDT).
- Most Recent 13F
- Q2 2026
- Location
- BOSTON, MA
- CIK
- 0001816307
- Portfolio Value
- $356.6M (Q1 2024)
- SEC Filing
- 0001420506-24-000871 ↗ filed May 15, 2024
Holdings Value
Holdings 72 stocks · $356.6M
| MRUS Merus NV | 7.15% | 566,287 | $25.5M | Reduce -12.3% |
| SLDB Solid Biosciences Inc. | 4.95% | 1,325,065 | $17.6M | Add +122.8% |
| MORF Morphic Holding Inc. | 4.78% | 483,972 | $17.0M | Reduce -3.2% |
| ORIC Oric Pharmaceuticals Inc. | 4.29% | 1,113,007 | $15.3M | Reduce -4.9% |
| MERSANA THERAPEUTICS INC | 3.73% | 2,968,798 | $13.3M | Reduce -53.8% |
| CLDX Celldex Therapeutics Inc. | 3.52% | 299,316 | $12.6M | Add +21.1% |
| RNAM Avidity Biosciences Inc. | 3.50% | 489,303 | $12.5M | New |
| NUVL Nuvalent Inc. Class A | 3.32% | 157,750 | $11.8M | Reduce -18.3% |
| CCCC C4 Therapeutics Inc. | 3.29% | 1,435,931 | $11.7M | New |
| PRAX Praxis Precision Medicines I | 3.26% | 190,556 | $11.6M | Reduce -32.9% |
| PSTX Poseida Therapeutics Inc. | 3.22% | 3,596,476 | $11.5M | Reduce -3.0% |
| AKRO Akero Therapeutics Inc. | 2.83% | 399,949 | $10.1M | Add +60.5% |
| CATX Perspective Therapeutics Inc. | 2.71% | 8,108,108 | $9.6M | New |
| RYTM Rhythm Pharmaceuticals Inc. | 2.23% | 183,776 | $8.0M | Add +5.5% |
| ALPN Alpine Immune Sciences Inc. | 2.21% | 199,020 | $7.9M | Reduce -33.2% |
| URGN Urogen Pharma Ltd. | 2.14% | 508,587 | $7.6M | Reduce -3.2% |
| GOSS Gossamer Bio Inc. | 2.03% | 6,130,268 | $7.2M | No change |
| MGNX Macrogenics Inc. | 1.97% | 478,079 | $7.0M | Reduce -62.0% |
| COGT Cogent Biosciences Inc. | 1.95% | 1,036,667 | $7.0M | Add +7.2% |
| KALV Kalvista Pharmaceuticals Inc. | 1.87% | 561,183 | $6.7M | Add +402.3% |
| KOD Kodiak Sciences Inc. | 1.83% | 1,238,822 | $6.5M | Add +23.9% |
| VCYT Veracyte Inc. | 1.74% | 280,773 | $6.2M | Add +13.3% |
| CRNX Crinetics Pharmaceuticals Inc. | 1.68% | 127,835 | $6.0M | New |
| OLMA Olema Pharmaceuticals Inc. | 1.64% | 515,317 | $5.8M | Reduce -10.2% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 1.46% | 500,000 | $5.2M | New |
| EYPT Eyepoint Inc. | 1.44% | 247,968 | $5.1M | New |
| BOLD Boundless Bio Inc. | 1.25% | 312,500 | $4.5M | New |
| TELA Tela Bio Inc. | 1.24% | 776,851 | $4.4M | Reduce -2.3% |
| BIIB Biogen Inc. | 1.17% | 19,365 | $4.2M | Reduce -3.2% |
| FULC Fulcrum Therapeutics Inc. | 1.05% | 398,436 | $3.8M | New |
| SRRK Scholar Rock Holding Corp. | 0.99% | 199,415 | $3.5M | Reduce -26.1% |
| CYTK Cytokinetics Inc. | 0.98% | 50,000 | $3.5M | New |
| APGE Apogee Therapeutics Inc. | 0.93% | 50,000 | $3.3M | New |
| JSPR Jasper Therapeutics Inc. | 0.90% | 109,892 | $3.2M | New |
| INSM Insmed Inc. | 0.86% | 113,616 | $3.1M | Reduce -26.9% |
| WVE Wave Life Sciences Ltd. | 0.86% | 495,471 | $3.1M | New |
| TRVI Trevi Therapeutics Inc. | 0.82% | 844,235 | $2.9M | Reduce -2.3% |
| XENE Xenon Pharmaceuticals Inc. | 0.80% | 66,090 | $2.8M | Reduce -59.5% |
| DXCM Dexcom Inc. | 0.78% | 20,000 | $2.8M | Reduce -35.5% |
| CERS Cerus Corp. | 0.78% | 1,465,744 | $2.8M | Reduce -2.3% |
| PLRX Pliant Therapeutics Inc. | 0.77% | 183,392 | $2.7M | Reduce -42.4% |
| RCKT Rocket Pharmaceuticals Inc. | 0.76% | 101,002 | $2.7M | Reduce -73.6% |
| CGEN Compugen Ltd. | 0.72% | 1,000,000 | $2.6M | Add +6.4% |
| ITCI Intra-Cellular Therapies Inc. | 0.68% | 34,807 | $2.4M | Reduce -56.5% |
| NAMS Newamsterdam Pharma Co. NV | 0.66% | 99,612 | $2.4M | New |
| EVOGENE LTD | 0.65% | 3,085,503 | $2.3M | Reduce -0.5% |
| ADCT Adc Therapeutics SA | 0.63% | 501,222 | $2.3M | New |
| VRNA Verona Pharma Ltd. | 0.62% | 136,714 | $2.2M | New |
| MIRM Mirum Pharmaceuticals Inc. | 0.56% | 79,194 | $2.0M | Reduce -2.0% |
| KRYS Krystal Biotech Inc. | 0.50% | 10,000 | $1.8M | New |
| MODULAR MED INC | 0.47% | 900,000 | $1.7M | New |
| TERN Terns Pharmaceuticals Inc. | 0.46% | 250,551 | $1.6M | Reduce -51.5% |
| VKTX Viking Therapeutics Inc. | 0.46% | 20,000 | $1.6M | New |
| AMLX Amylyx Pharmaceuticals Inc. | 0.40% | 500,000 | $1.4M | New |
| CRBP Corbus Pharmaceuticals Holdi | 0.35% | 31,980 | $1.3M | New |
| GUTS Fractyl Health Inc. | 0.35% | 166,666 | $1.2M | New |
| ETNB 89BIO Inc. | 0.30% | 92,298 | $1.1M | Reduce -41.9% |
| ABVX Abivax SA-ADR | 0.30% | 75,000 | $1.1M | New |
| ZURA Zura Bio Ltd. | 0.24% | 328,504 | $844K | Reduce -29.1% |
| KPTI Karyopharm Therapeutics Inc. | 0.24% | 558,466 | $843K | Reduce -0.6% |
| GERN Geron Corp. | 0.23% | 250,000 | $825K | New |
| MTEMQ Molecular Templates Inc. | 0.22% | 354,608 | $794K | No change |
| ACET Adicet Bio Inc. | 0.22% | 331,279 | $779K | New |
| MLYS Mineralys Therapeutics Inc. | 0.21% | 56,944 | $735K | New |
| ALGS Aligos Therapeutics Inc. | 0.18% | 655,515 | $642K | Reduce -1.9% |
| RLMD Relmada Therapeutics Inc. | 0.13% | 99,379 | $462K | Reduce -0.6% |
| ERAS Erasca Inc. | 0.13% | 223,845 | $461K | New |
| GPCR Structure Therapeutics Inc. | 0.12% | 10,000 | $429K | New |
| RZLT Rezolute Inc. | 0.11% | 151,985 | $388K | Reduce -3.3% |
| VYNE THERAPEUTICS INC | 0.07% | 86,383 | $265K | New |
| ELUT Elutia Inc. | 0.07% | 78,580 | $248K | New |
| IMNM Immunome Inc. | 0.05% | 7,489 | $185K | New |
Options reported separately and not counted above: MACROGENICS INC calls ($2.1M), C4 THERAPEUTICS INC calls ($1.2M), AMYLYX PHARMACEUTICALS INC calls ($57K), MERSANA THERAPEUTICS INC calls ($8K).
Other holdings (1): bonds, preferreds, convertibles and warrants · $31K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| RCKTW Rocket Pharmaceuticals in-27 | *W EXP 09/02/202 | 104,828 | $31K | No change |
Total filed on the 13F, all lines: $356.6M.
Portfolio Sells Q4 2023 → Q1 2024
| MDT Medtronic PLC | Sold out | 0.00% | −3.43 |
| SNY Sanofi-ADR | Sold out | 0.00% | −3.37 |
| RCKT Rocket Pharmaceuticals Inc. | Reduce -73.6% | 0.76% | −2.77 |
| MGNX Macrogenics Inc. | Reduce -62.0% | 1.97% | −1.76 |
| ISRG Intuitive Surgical Inc. | Sold out | 0.00% | −1.65 |
| CBAY Cymabay Therapeutics Inc. | Sold out | 0.00% | −1.60 |
| CRBU Caribou Biosciences Inc. | Sold out | 0.00% | −1.59 |
| PEN Penumbra Inc. | Sold out | 0.00% | −1.55 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -59.5% | 0.80% | −1.52 |
| SRPT Sarepta Therapeutics Inc. | Sold out | 0.00% | −1.39 |
| UTHR United Therapeutics Corp. | Sold out | 0.00% | −1.11 |
| ITCI Intra-Cellular Therapies Inc. | Reduce -56.5% | 0.68% | −1.09 |
| NUVL Nuvalent Inc. Class A | Reduce -18.3% | 3.32% | −1.06 |
| PLRX Pliant Therapeutics Inc. | Reduce -42.4% | 0.77% | −1.01 |
| BHVN Biohaven Ltd. | Sold out | 0.00% | −0.93 |
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −0.93 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −0.91 |
| MERSANA THERAPEUTICS INC | Reduce -53.8% | 3.73% | −0.86 |
| OLMA Olema Pharmaceuticals Inc. | Reduce -10.2% | 1.64% | −0.85 |
| PSTX Poseida Therapeutics Inc. | Reduce -3.0% | 3.22% | −0.62 |
| INSM Insmed Inc. | Reduce -26.9% | 0.86% | −0.62 |
| ANNX Annexon Inc. | Sold out | 0.00% | −0.58 |
| TERN Terns Pharmaceuticals Inc. | Reduce -51.5% | 0.46% | −0.57 |
| SRRK Scholar Rock Holding Corp. | Reduce -26.1% | 0.99% | −0.57 |
| ARGX Argenx SE - ADR | Sold out | 0.00% | −0.57 |
| PMVP PMV Pharmaceuticals Inc. | Sold out | 0.00% | −0.53 |
| ALT Altimmune Inc. | Sold out | 0.00% | −0.52 |
| NTLA Intellia Therapeutics Inc. | Sold out | 0.00% | −0.52 |
| BCRX Biocryst Pharmaceuticals Inc. | Sold out | 0.00% | −0.46 |
| ZURA Zura Bio Ltd. | Reduce -29.1% | 0.24% | −0.43 |
| BIIB Biogen Inc. | Reduce -3.2% | 1.17% | −0.43 |
| DXCM Dexcom Inc. | Reduce -35.5% | 0.78% | −0.41 |
| TELA Tela Bio Inc. | Reduce -2.3% | 1.24% | −0.39 |
| SDGR Schrodinger Inc. | Sold out | 0.00% | −0.34 |
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −0.34 |
| URGN Urogen Pharma Ltd. | Reduce -3.2% | 2.14% | −0.29 |
| IMVT Immunovant Inc. | Sold out | 0.00% | −0.26 |
| ETNB 89BIO Inc. | Reduce -41.9% | 0.30% | −0.25 |
| CERS Cerus Corp. | Reduce -2.3% | 0.78% | −0.22 |
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −0.18 |
| MIRM Mirum Pharmaceuticals Inc. | Reduce -2.0% | 0.56% | −0.18 |
| EVOGENE LTD | Reduce -0.5% | 0.65% | −0.15 |
| RLMD Relmada Therapeutics Inc. | Reduce -0.6% | 0.13% | +0.00 |
| ALGS Aligos Therapeutics Inc. | Reduce -1.9% | 0.18% | +0.04 |
| RZLT Rezolute Inc. | Reduce -3.3% | 0.11% | +0.06 |
| KPTI Karyopharm Therapeutics Inc. | Reduce -0.6% | 0.24% | +0.09 |
| MORF Morphic Holding Inc. | Reduce -3.2% | 4.78% | +0.32 |
| TRVI Trevi Therapeutics Inc. | Reduce -2.3% | 0.82% | +0.46 |
| ALPN Alpine Immune Sciences Inc. | Reduce -33.2% | 2.21% | +0.46 |
| ORIC Oric Pharmaceuticals Inc. | Reduce -4.9% | 4.29% | +0.97 |
Portfolio Buys Q4 2023 → Q1 2024
| SLDB Solid Biosciences Inc. | Add +122.8% | 4.95% | +3.82 |
| RNAM Avidity Biosciences Inc. | New | 3.50% | +3.50 |
| CCCC C4 Therapeutics Inc. | New | 3.29% | +3.29 |
| CATX Perspective Therapeutics Inc. | New | 2.71% | +2.71 |
| CRNX Crinetics Pharmaceuticals Inc. | New | 1.68% | +1.68 |
| BBOT Bridgebio Oncology Therapeut | New | 1.46% | +1.46 |
| KALV Kalvista Pharmaceuticals Inc. | Add +402.3% | 1.87% | +1.44 |
| EYPT Eyepoint Inc. | New | 1.44% | +1.44 |
| BOLD Boundless Bio Inc. | New | 1.25% | +1.25 |
| FULC Fulcrum Therapeutics Inc. | New | 1.05% | +1.05 |
| AKRO Akero Therapeutics Inc. | Add +60.5% | 2.83% | +1.04 |
| CYTK Cytokinetics Inc. | New | 0.98% | +0.98 |
| APGE Apogee Therapeutics Inc. | New | 0.93% | +0.93 |
| JSPR Jasper Therapeutics Inc. | New | 0.90% | +0.90 |
| KOD Kodiak Sciences Inc. | Add +23.9% | 1.83% | +0.89 |
| WVE Wave Life Sciences Ltd. | New | 0.86% | +0.86 |
| NAMS Newamsterdam Pharma Co. NV | New | 0.66% | +0.66 |
| ADCT Adc Therapeutics SA | New | 0.63% | +0.63 |
| VRNA Verona Pharma Ltd. | New | 0.62% | +0.62 |
| KRYS Krystal Biotech Inc. | New | 0.50% | +0.50 |
| CLDX Celldex Therapeutics Inc. | Add +21.1% | 3.52% | +0.50 |
| MODULAR MED INC | New | 0.47% | +0.47 |
| VKTX Viking Therapeutics Inc. | New | 0.46% | +0.46 |
| AMLX Amylyx Pharmaceuticals Inc. | New | 0.40% | +0.40 |
| CRBP Corbus Pharmaceuticals Holdi | New | 0.35% | +0.35 |
| GUTS Fractyl Health Inc. | New | 0.35% | +0.35 |
| ABVX Abivax SA-ADR | New | 0.30% | +0.30 |
| GERN Geron Corp. | New | 0.23% | +0.23 |
| ACET Adicet Bio Inc. | New | 0.22% | +0.22 |
| MLYS Mineralys Therapeutics Inc. | New | 0.21% | +0.21 |
| COGT Cogent Biosciences Inc. | Add +7.2% | 1.95% | +0.20 |
| CGEN Compugen Ltd. | Add +6.4% | 0.72% | +0.15 |
| ERAS Erasca Inc. | New | 0.13% | +0.13 |
| GPCR Structure Therapeutics Inc. | New | 0.12% | +0.12 |
| VYNE THERAPEUTICS INC | New | 0.07% | +0.07 |
| ELUT Elutia Inc. | New | 0.07% | +0.07 |
| IMNM Immunome Inc. | New | 0.05% | +0.05 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +5.5% | 2.23% | −0.24 |
| VCYT Veracyte Inc. | Add +13.3% | 1.74% | −0.36 |
Options Activity Q4 2023 → Q1 2024
| MRTX Mirati Therapeutics Inc. | call | Sold out | 150,000 | $8.8Mbefore exit |
| KALV Kalvista Pharmaceuticals Inc. | call | Sold out | 180,400 | $2.2Mbefore exit |
| MACROGENICS INC | call | New | 145,500 | $2.1M |
| C4 THERAPEUTICS INC | call | New | 150,000 | $1.2M |
| MERSANA THERAPEUTICS INC | call | Sold out | 301,600 | $700Kbefore exit |
| AMYLYX PHARMACEUTICALS INC | call | New | 20,000 | $57K |
| MERSANA THERAPEUTICS INC | call | New | 1,700 | $8K |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 64 | $898.5M | ASND, CELC, COGT, URGN, IMNM |
| Q1 2026 | 66 | $848.6M | KALV, DNTH, COGT, CELC, IMNM |
| Q4 2025 | 63 | $691.1M | ABVX, COGT, URGN, KALV, CELC |
| Q3 2025 | 72 | $690.7M | ABVX, RYTM, RNAM, NUVL, URGN |
| Q2 2025 | 56 | $488.6M | MRUS, AKRO, VRNA, URGN, RYTM |
| Q1 2025 | 66 | $478.6M | VRNA, MRUS, NUVL, AKRO, INSM |
| Q4 2024 | 57 | $447.2M | NUVL, MRUS, INSM, VRNA, AKRO |
| Q3 2024 | 67 | $443.7M | NUVL, MRUS, INSM, RNAM, ERAS |
| Q2 2024 | 65 | $405.1M | MRUS, NUVL, RNAM, URGN, ERAS |
| Q1 2024 | 72 | $356.6M | MRUS, SLDB, MORF, ORIC, MERSANA THERAPEUTICS INC |